Trial reportWorld journal of gastroenterology2010
Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C.
Trial report in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial.
Evaluation of the Effect of the Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Metastatic Colorectal Adenocarcinoma. Phase II
Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip
Exploratory Study to Evaluate the Effect and Safety of the Use of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antioxidant supplements for liver diseases.The Cochrane database of systematic reviews · 2011Pooled it
- Quantitative Characterization of the Serum Elemental Signatures in HBV Infection.Biological trace element research · 2026Article
- Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells.Journal of physiology and biochemistry · 2023Article
- Ocoxin oral solution demonstrates antiviral properties in cellular models.Experimental and therapeutic medicine · 2021Article
- Ocoxin as a complement to first line treatments in cancer.International journal of medical sciences · 2021Review
- Article
- Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma.Oxidative medicine and cellular longevity · 2019Article
- Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer.International journal of oncology · 2018Article
- Antitumoral effect of Ocoxin in hepatocellular carcinoma.Oncology letters · 2017Article
- Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice.Oncology reports · 2016Article
- Antitumoral effect of Ocoxin on acute myeloid leukemia.Oncotarget · 2016Article
- Oxidative stress modulation in hepatitis C virus infected cells.World journal of hepatology · 2015Review
- Immunomodulatory effect of an isolated fraction from Tinospora crispa on intracellular expression of INF-γ, IL-6 and IL-8.BMC complementary and alternative medicine · 2014Article
- Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway.World journal of gastroenterology · 2014Review
- Effects of kalsis, a dietary supplement, on bone metabolism in the ovariectomized rats.Journal of osteoporosis · 2012Article
- Antioxidants as therapeutic agents for liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the efficacy of Viusid, a nutritional supplement, as an antioxidant and an immunomodulator in patients with chronic hepatitis C.
methodsSixty patients with chronic hepatitis C who were non-responders to standard antiviral treatment were randomly assigned to receive Viusid (3 sachets daily, n = 30) or placebo (n = 30) for 24 wk. The primary outcome was the change in serum malondialdehyde and 4-hydroxyalkenals (lipid peroxidation products). Secondary outcomes were changes in serum tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and interleukin-10 (IL-10).
resultsStatistically significant reductions in serum 4-hydroxyalkenals and malondialdehyde levels were observed in both groups in comparison with pretreatment values, but the patients who received Viusid showed a more marked reduction as compared with the control group (P = 0.001). TNF-alpha levels significantly increased from 6.9 to 16.2 pg/mL (P < 0.01) in the patients who received placebo in comparison with almost unchanged levels, from 6.6 to 7.1 pg/mL (P = 0.26), in the patients treated with Viusid (P = 0.001). In addition, IL-10 levels were markedly increased in the patients treated with Viusid (from 2.6 to 8.3 pg/mL, P = 0.04) in contrast to the patients assigned to placebo (from 2.8 to 4.1 pg/mL, P = 0.09) (P = 0.01). Likewise, the administration of Viusid markedly increased mean IFN-gamma levels from 1.92 to 2.89 pg/mL (P < 0.001) in comparison with a reduction in mean levels from 1.80 to 1.68 pg/mL (P = 0.70) in the placebo group (P < 0.0001). Viusid administration was well tolerated.
conclusionOur results indicate that treatment with Viusid leads to a notable improvement of oxidative stress and immunological parameters in patients with chronic hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.